Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.55 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186610 | 1.00 | GABBR2 (0.55) | GABBR2GABBR1LMNAKDM4EL3MBTL1 | |
| SCHEMBL904476 | 1.00 | GABBR2 (0.55) | GABBR2GABBR1LMNAKDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1374836 | 0.98 | GABBR2 (0.53) | GABBR2GABBR1LMNAKDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1373206 | 0.98 | GABBR2 (0.53) | GABBR2GABBR1LMNAKDM4EL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL2341560 | 0.98 | GABBR2 (0.53) | GABBR2GABBR1LMNAKDM4EL3MBTL1 | |
| Thiophene SCHEMBL27621795 | 0.88 | GABBR2 (0.46) | GABBR2GABBR1LMNAKDM4EL3MBTL1 | |
| SCHEMBL27694460 | 0.87 | FFAR1 (0.57) | GABBR2GABBR1LMNA | |
| SCHEMBL9061130 | 0.86 | LMNA (0.54) | GABBR2GABBR1LMNAKDM4EL3MBTL1 | |
| SCHEMBL28580617 | 0.83 | GABBR2 (0.48) | GABBR2GABBR1LMNAKDM4EL3MBTL1 | |
| SCHEMBL5384514 | 0.83 | KDM4E (0.50) | GABBR2GABBR1LMNAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116735758-B | Method for detecting 55 organic acids and sugar alcohols in urine by gas chromatography-tandem mass spectrometry technology | 北京凯莱谱生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-109232220-B | Chemical resolution method of 3-hydroxy-3-phenylpropionic acid compound | 上海健康医学院 | 2021-09-10 | — | — | CN | claimed |
| JP-3236785-A | — | — | None | — | — | JP | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0542300-B1 | Method of preparing (S)-1-phenyl-1,3-propanediol or derivatives thereof | AJINOMOTO KK (JP) | 1997-02-26 | — | — | EP | disclosed |
| US-5393664-A | Using a culture product | AJINOMOTO CO. INC. (JP) | 1995-02-28 | — | — | US | disclosed |
| EP-0494203-B1 | SYNTHESIS OF ARYL ALKANEDIOLS HAVING HIGH OPTICAL PURITY | EASTMAN KODAK CO (US) | 1993-12-08 | — | — | EP | disclosed |
| EP-0542300-A2 | Method of preparing (S)-1-phenyl-1,3-propanediol or derivatives thereof | Ajinomoto Co., Inc. (JP) | 1993-05-19 | — | — | EP | disclosed |
| JP-H03236785-A | PRODUCTION OF OPTICALLY ACTIVE (S)-3-PHENYL-3-HYDROXYPROPIONIC ACID DERIVATIVE | KANEGAFUCHI CHEM IND CO LTD | 1991-10-22 | — | — | JP | disclosed |
| WO-1991004334-A1 | SYNTHESIS OF ARYL ALKANEDIOLS HAVING HIGH OPTICAL PURITY | EASTMAN KODAK COMPANY (US) | 1991-04-04 | — | — | WO | disclosed |
| US-4921798-A | Synthesis of (aryl or arylalkyl)-3-hydroxy propionic acids and aryl alkanediols having high optical purity | EASTMAN KODAK COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| US-4921798-A | Synthesis of (aryl or arylalkyl)-3-hydroxy propionic acids and aryl alkanediols having high optical purity | EASTMAN KODAK COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | GABBR2 2953/4885GABBR1 3660/4885LMNA 2193/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | GABBR2 4401/4885GABBR1 4544/4885LMNA 1458/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | GABBR2 4401/4885GABBR1 4544/4885LMNA 1458/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | GABBR2 2953/4885GABBR1 3660/4885LMNA 2193/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | GABBR2 2953/4885GABBR1 3660/4885LMNA 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.